VonosapPack is a fixed-dose combination medicinal product for the eradication of Helicobacter pylori. To ensure efficacy and avoid risks, it is essential to clarify its indications, strictly adhere to contraindications, and pay attention to safety in special populations before administration.

1. Indications

VonosapPack is indicated for Helicobacter pylori infections susceptible to amoxicillin and clarithromycin. Approved indications include:

Peptic ulcer disease: Gastric ulcer and duodenal ulcer positive for Helicobacter pylori.

Gastric MALT lymphoma: Only applicable for early-stage lesions; the efficacy of eradication therapy for advanced gastric MALT lymphoma has not been established.

Immune thrombocytopenia: Recommended only for patients judged likely to benefit from eradication therapy after guideline-based evaluation.

Post-endoscopic treatment of early gastric cancer: For the prevention of metachronous gastric cancer; the efficacy for gastric cancer prevention in other settings has not been established.

Helicobacter pylori-positive gastritis: To be used only after the infection is confirmed by both endoscopy and pathological examination.

2. Core Contraindications

The product is contraindicated in the following conditions, as severe adverse outcomes may occur:

Hypersensitivity: Patients with a history of hypersensitivity to any component of the product (vonoprazan fumarate, amoxicillin, clarithromycin).

Concomitant use of specific medicinal products: Patients receiving atazanavir, rilpivirine, pimozide, ergot alkaloids, domperidone, etc. (see Section 2.2 of the Prescribing Information for details), due to the risk of severe toxicity or loss of efficacy.

Infectious mononucleosis: Amoxicillin significantly increases the risk of rash in these patients.

Severe renal impairment: Drug excretion is impaired, leading to abnormally elevated plasma concentrations; individual dose adjustment is not feasible with this fixed-dose combination.

Patients with hepatic or renal impairment receiving colchicine: Clarithromycin significantly increases plasma colchicine concentrations, which may result in fatal toxicity.

3. Use in Special Populations

3.1 Pregnant and lactating women

Use only if the therapeutic benefit clearly outweighs the potential risk.

Animal studies have shown fetal toxicity with both clarithromycin and vonoprazan.

Amoxicillin and clarithromycin are excreted into breast milk; a risk‑benefit assessment is required for use during lactation.

3.2 Paediatric population

Safety and efficacy in children have not been established; use is not recommended in principle.

3.3 Elderly

Physiological function is decreased, drugs are more likely to accumulate, and bleeding tendency associated with vitamin K deficiency may occur more readily; close monitoring is required.

3.4 Renal impairment

Use with caution in mild to moderate impairment, due to delayed excretion and elevated plasma concentrations of vonoprazan and clarithromycin.

Contraindicated in severe renal impairment.

3.5 Hepatic impairment

Vonoprazan metabolism is reduced with increased plasma concentrations; clarithromycin may exacerbate liver injury.

Contraindicated in patients with liver disease receiving colchicine.

3.6 Patients with cardiac disease or hypokalaemia

Clarithromycin may prolong the QT interval and induce serious cardiac arrhythmias; use with caution and close monitoring.